Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737588 | 0.86 | CYP2C9 (0.32) | TDP1LMNAL3MBTL1TSHR | |
| SCHEMBL2305046 | 0.86 | TDP1 (0.44) | TDP1LMNAL3MBTL1TSHRKDM4E | |
| SCHEMBL14781398 | 0.81 | TDP1 (0.40) | TDP1LMNAL3MBTL1TSHRKDM4E | |
| SCHEMBL15800142 | 0.81 | TDP1 (0.40) | TDP1LMNAL3MBTL1TSHRKDM4E | |
| SCHEMBL25870351 | 0.81 | TDP1 (0.40) | TDP1LMNAL3MBTL1TSHRKDM4E | |
| SCHEMBL23819364 | 0.81 | TDP1 (0.40) | TDP1TSHR | |
| SCHEMBL16729297 | 0.79 | TDP1 (0.38) | TDP1LMNAL3MBTL1TSHRKDM4E | |
| SCHEMBL14599632 | 0.79 | TDP1 (0.38) | TDP1LMNAL3MBTL1TSHRKDM4E | |
| SCHEMBL15731250 | 0.79 | TDP1 (0.38) | TDP1LMNAL3MBTL1TSHRKDM4E | |
| SCHEMBL16729401 | 0.79 | TDP1 (0.38) | TDP1LMNAL3MBTL1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012097052-A2 | MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES | INTERTECH BIO, LLC (US) | 2012-07-19 | — | — | WO | disclosed |
| US-20120114595-A1 | SUGAR CHAIN-ADDED AILIM EXTRACELLULAR DOMAIN AND METHOD FOR PRODUCING SAME | OTSUKA CHEMICAL CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| EP-2052252-B1 | LUMINESCENT LANTHANIDE LABELLING REAGENTS AND THEIR USE | ABACUS DIAGNOSTICA OY (FI) | 2010-11-10 | — | — | EP | disclosed |
| EP-1938836-A1 | Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells | UNIVERSITE RENE DESCARTES (PARIS V) (FR) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114595-A1 | SUGAR CHAIN-ADDED AILIM EXTRACELLULAR DOMAIN AND METHOD FOR PRODUCING SAME | SIGLEC7, ENGASE, SIGLEC9 | TDP1 3396/4885LMNA 2462/4885L3MBTL1 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.